OSI-906 (Linsitinib)

Catalog No.S1091

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

OSI-906 (Linsitinib) Chemical Structure

OSI-906 (Linsitinib) Chemical Structure
Molecular Weight: 421.49

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

IGF-1R Inhibitors with Unique Features

  • Pan IGF-1R Inhibitor

    GSK1904529A Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • Most Potent IGF-1R Inhibitor

    BMS-754807 IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • IGF-1R Inhibitor in Clinical Trial

    BMS-754807 Phase II for Breast Cancer.

  • Newest IGF-1R Inhibitor

    PQ 401 Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Product Information

  • Compare IGF-1R Inhibitors
    Compare IGF-1R Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)

 View  More

IC50 35 nM 75 nM 75 nM >10 μM
In vitro OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-FukMonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\RTWM2OD1yLkCyPFA3KM7:TR?=MmPBV2FPT0WU
KS-1M2Wwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrxTWM2OD1yLkCzPFM2KM7:TR?=NWf1N4ZlW0GQR1XS
TE-11NGjlTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mom1TWM2OD1yLkC3PFIzKM7:TR?=NVjZc2ltW0GQR1XS
EW-1MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTRTWM2OD1yLkC4OVg2KM7:TR?=MUHTRW5ITVJ?
HMV-IINW\GWXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHq2fI5KSzVyPUCuNFg5PDZizszNMVLTRW5ITVJ?
COLO-205MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYn4R5c3UUN3ME2wMlExPDV2IN88US=>Mm[5V2FPT0WU
ES1M2PqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPDTWM2OD1yLkGwOlk3KM7:TR?=M1n1eXNCVkeHUh?=
GDM-1Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4SwTWlEPTB;MD6xN|Y4OiEQvF2=MlnrV2FPT0WU
ML-2MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mle3TWM2OD1yLkG1PFk3KM7:TR?=NXTFfos{W0GQR1XS
Saos-2NWj0NFg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfi[Vc4UUN3ME2wMlE3PTJ4IN88US=>MYPTRW5ITVJ?
NCI-H1355M{\DPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTBwMUixN|Uh|ryPMlHjV2FPT0WU
G-401NXzFXXN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fU[mlEPTB;MD6xPFI{KM7:TR?=M3OwOXNCVkeHUh?=
EW-16M3LyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTBwMUi3O|ch|ryPM4LUbXNCVkeHUh?=
EW-7MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TRZWlEPTB;MD6xPFg5OSEQvF2=NEeyW|lUSU6JRWK=
NCI-H727NYTqNJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTBwMUm3PVQh|ryPM4Hyb3NCVkeHUh?=
LCLC-97TM1MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwMkC5OVUh|ryPM2rCbHNCVkeHUh?=
NCI-H650Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPtTWM2OD1yLkKxN|g1KM7:TR?=Mn7BV2FPT0WU
NCI-H2122M3fmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4X3SWlEPTB;MD6yN|I6QSEQvF2=MYTTRW5ITVJ?
SK-N-DZMkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHrTWM2OD1yLkKzOlk5KM7:TR?=NWL6bFlSW0GQR1XS
HT-29M2izPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTBwMkSyOFgh|ryPNFPl[XBUSU6JRWK=
LB771-HNCMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXq2XppvUUN3ME2wMlI2QTF3IN88US=>NXfjNYpCW0GQR1XS
HT-144M2S0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HJNmlEPTB;MD6yOlE6OSEQvF2=MonVV2FPT0WU
LAN-6M3zWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3P4eGlEPTB;MD6yOlM1QCEQvF2=NIHCbHFUSU6JRWK=
EW-18NV34[2JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHyTWM2OD1yLkK3NFAyKM7:TR?=NH;VXXlUSU6JRWK=
LS-1034MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTQXVhTUUN3ME2wMlI4OTN{IN88US=>NV\UW4JTW0GQR1XS
EW-11MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTBwMki0N|Ih|ryPNVuxU5o1W0GQR1XS
SNU-C1NWjQbHg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1SzdmlEPTB;MD6yPVMyOyEQvF2=MXHTRW5ITVJ?
RS4-11MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTBwM{O3OVgh|ryPNFTmd5RUSU6JRWK=
ES4MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzDTWM2OD1yLkSxNFM5KM7:TR?=NXHEZ5BwW0GQR1XS
COLO-320-HSRM3jR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXX1WllSUUN3ME2wMlQyOzZ6IN88US=>MnzaV2FPT0WU
NB10MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXKTWM2OD1yLkS1OFM4KM7:TR?=NFPrWpNUSU6JRWK=
BFTC-905NYDrZoJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PlUGlEPTB;MD60Olc2QCEQvF2=MUHTRW5ITVJ?
A375M{nPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\BTWM2OD1yLkS3OlE4KM7:TR?=NInJeFVUSU6JRWK=
SJRH30Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVX4enE5UUN3ME2wMlUxQDJ{IN88US=>M4H5SXNCVkeHUh?=
NOS-1NGXPXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnHZnFnUUN3ME2wMlUzOjZ5IN88US=>NHq5XZhUSU6JRWK=
SIG-M5NWL1XZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWW4coNqUUN3ME2wMlU{PTV5IN88US=>MWnTRW5ITVJ?
DOKMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHOxS5FKSzVyPUCuOVU3KM7:TR?=MlP0V2FPT0WU
NB69NX;2PW97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3Sem1KSzVyPUCuOVgzPTdizszNMXnTRW5ITVJ?
SK-NEP-1M3;QWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTBwNkCyN|Yh|ryPM3nqRXNCVkeHUh?=
SK-MM-2MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTBwNkW0PVEh|ryPNXLXflFmW0GQR1XS
NCI-H358MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknzTWM2OD1yLk[3NFgzKM7:TR?=Mo\aV2FPT0WU
RH-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDqeWxKSzVyPUCuO|Q5PTlizszNNVS5epg5W0GQR1XS
NH-12NXTsU5l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmiyTWM2OD1yLke2NFQ3KM7:TR?=MlvyV2FPT0WU
TE-12M1i5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGH2ZZNKSzVyPUCuO|Y1QDZizszNM3LSOHNCVkeHUh?=
COLO-668MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\UU2lEPTB;MD64OFY3PiEQvF2=NVHH[GxUW0GQR1XS
PANC-08-13MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fzV2lEPTB;MD64OlM4PyEQvF2=MVrTRW5ITVJ?
HCC2998MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlm1TWM2OD1yLki4NlY{KM7:TR?=NX\oPFBXW0GQR1XS
ABC-1M3LQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37Yc2lEPTB;MD65NFM2OiEQvF2=MoH1V2FPT0WU
ES6MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrlR4NKSzVyPUCuPVExPjZizszNM4D4V3NCVkeHUh?=
SNU-387NH\vTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;xTWM2OD1yLkm5N|k{KM7:TR?=M4nVdnNCVkeHUh?=
CMKNXLadWxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfXVnpKSzVyPUCuPVk6OjlizszNM1HMO3NCVkeHUh?=
SJSA-1NXzzSlBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXaT|FKSzVyPUGuNFM3PTNizszNNVXiNVVzW0GQR1XS
SIMAMkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjXOlR7UUN3ME2xMlA3QDJ3IN88US=>M{Wy[HNCVkeHUh?=
ES3MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3X5XmlEPTB;MT6xNlI6PyEQvF2=MVzTRW5ITVJ?
IGROV-1M3niSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HNSGlEPTB;MT6xOVQ1PCEQvF2=NYXXTZdCW0GQR1XS
MEL-JUSOM4Hlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnO3TWM2OD1zLkG1O|U6KM7:TR?=NID0[ppUSU6JRWK=
T84Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfuZoFKSzVyPUGuNlA6OTRizszNMkH1V2FPT0WU
CAL-85-1Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fsUWlEPTB;MT6yN|E{QCEQvF2=M1mwRnNCVkeHUh?=
RDMnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TTN2lEPTB;MT6yOlQ2PSEQvF2=MorxV2FPT0WU
TE-8MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;LcXhDUUN3ME2xMlMyPDZ{IN88US=>M2XoSXNCVkeHUh?=
L-363MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTFwM{SyNFgh|ryPMo[0V2FPT0WU
EKVXMljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTFwM{S1Olgh|ryPMXPTRW5ITVJ?
SK-MEL-3MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfGdHZKSzVyPUGuOFg2PTZizszNMkfwV2FPT0WU
TGBC24TKBM{nScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTFwNUCxPVMh|ryPM2mwNnNCVkeHUh?=
NCI-H1770NYfqfGY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTFwNUGxNVMh|ryPNYHnfI5RW0GQR1XS
HuH-7Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PFWmlEPTB;MT62NFA6QCEQvF2=MmfTV2FPT0WU
HL-60NVW5bGNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTFwNk[5Nlgh|ryPMl\WV2FPT0WU
TE-1NEH2PHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTFwN{C5OFUh|ryPNH7XOWJUSU6JRWK=
LC-2-adNY\ET3JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVH6XWlMUUN3ME2xMlc{QDh5IN88US=>MmLzV2FPT0WU
LB647-SCLCMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnSTWM2OD1zLke2OVg{KM7:TR?=NGXYUY9USU6JRWK=
NCI-H2171NXzWfYVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTFwN{e3NVYh|ryPNYr2[oZQW0GQR1XS
SK-PN-DWNGXmXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTFwOUGyPVgh|ryPMojYV2FPT0WU
MC-IXCNYHq[pk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzQRWRLUUN3ME2xMlk5QThizszNNEfQfFBUSU6JRWK=
LS-513NX\WPHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHNTWM2OD1{LkC1N|A2KM7:TR?=NUH2Z5RXW0GQR1XS
EW-3M2jwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTJwMEm4OFQh|ryPNWr5TY5VW0GQR1XS
OPM-2MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nRTGlEPTB;Mj6xNFIh|ryPMXLTRW5ITVJ?
LP-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnRemV{UUN3ME2yMlI2QDB5IN88US=>MVvTRW5ITVJ?
LU-134-ANET3Nm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{Pte2lEPTB;Mj6yO|ch|ryPM2rGSnNCVkeHUh?=
CP66-MELNWL1c3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\tbGlEPTB;Mj6yPVAyPCEQvF2=NIXYU2dUSU6JRWK=
HCC1143NVW4c5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTJwNEWzOlgh|ryPM1PqOXNCVkeHUh?=
LOXIMVIM1nrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDmPVhKSzVyPUKuOlAzOSEQvF2=NGjLWYZUSU6JRWK=
TE-10M1fyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTHeVdKSzVyPUKuO|A5OzhizszNNFfSWHFUSU6JRWK=
NCI-H1882M1WxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7UTWM2OD1{Lke1NlI4KM7:TR?=Ml3wV2FPT0WU
CHP-126M2HVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjBU4JKSzVyPUKuO|Y{OTdizszNNX[yW3dFW0GQR1XS
NCI-H1623NH3YR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TIbWlEPTB;Mj65NlAzPCEQvF2=MoPWV2FPT0WU
GB-1NULlTG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4O5UmlEPTB;Mj65N|QxPCEQvF2=MYPTRW5ITVJ?
RCC10RGBMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3PTWM2OD1{Lkm1NlgyKM7:TR?=MV\TRW5ITVJ?
NCI-H2141NVTuOnhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrDTWM2OD1{Lkm2PFk3KM7:TR?=MnHKV2FPT0WU
GI-ME-NNIjTfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTNwMEC1OlUh|ryPMknMV2FPT0WU
NCI-H526NHvkU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGqweW9KSzVyPUOuNFQxQDVizszNMoTHV2FPT0WU
NCI-H747NVzpRXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrsSI9KSzVyPUOuNFQ6QTJizszNM3PUbnNCVkeHUh?=
SNU-423NFvJ[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7uUXpKSzVyPUOuNlA{OTNizszNNVe0bm96W0GQR1XS
A427NWfsZ2pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfsV|J2UUN3ME2zMlI2Pjl7IN88US=>Mnn2V2FPT0WU
CAL-12TMnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLkfIpMUUN3ME2zMlQxPzF|IN88US=>MWPTRW5ITVJ?
LU-99AMlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrld|l6UUN3ME2zMlQ4OTB3IN88US=>MmSwV2FPT0WU
MS-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDPTWM2OD1|LkWzOFI6KM7:TR?=NHHDSG1USU6JRWK=
SK-LU-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHnTWM2OD1|Lke2Nlk2KM7:TR?=MXXTRW5ITVJ?
SW837MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHX0R4FKSzVyPUOuO|Y{OzNizszNNILpXlZUSU6JRWK=
ES8MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLHTWM2OD1|LkizPFc4KM7:TR?=NIOwfZRUSU6JRWK=
MZ2-MELMlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTMTWM2OD1|LkmyNFg3KM7:TR?=MoXJV2FPT0WU
TGWNFroZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vVVWlEPTB;ND6wNVMyOSEQvF2=M1:zSnNCVkeHUh?=
GP5dMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWC2PI1iUUN3ME20MlA2OzZ{IN88US=>NUm5fYttW0GQR1XS
BB49-HNCM1\FWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTRwMUWyNVMh|ryPM3HUVXNCVkeHUh?=
NB13NFSwT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYSxclY1UUN3ME20MlI3QDh5IN88US=>M2nsZ3NCVkeHUh?=
NTERA-S-cl-D1NH7SfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojXTWM2OD12LkK4OlE2KM7:TR?=M4\EV3NCVkeHUh?=
NCI-H1648M3u0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTRwMkm4NVkh|ryPMlu0V2FPT0WU
LCLC-103HMnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fxNGlEPTB;ND6zNlE6PSEQvF2=M3npd3NCVkeHUh?=
LS-411NNV7KdZExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\WZpI1UUN3ME20MlQ1QDh3IN88US=>MV;TRW5ITVJ?
NCI-H1092MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLuTWM2OD12LkS1Olg4KM7:TR?=MYfTRW5ITVJ?
PANC-10-05NGL5d4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUmz[ot3UUN3ME20MlY6QDRizszNM4LwXHNCVkeHUh?=
DK-MGMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTRwOEC5N|Mh|ryPMnzKV2FPT0WU
OVCAR-5M4\OOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV62RZRZUUN3ME20MlgyOjJ4IN88US=>NYLjc2ZTW0GQR1XS
CAL-39MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDZTWM2OD12Lki3Olch|ryPNX;4ZmZkW0GQR1XS
TE-441-TMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmeyTWM2OD12LkmwOVM4KM7:TR?=NH\PPYFUSU6JRWK=
MOLT-16NXn6UXNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTRwOUWyOVMh|ryPM2fJTHNCVkeHUh?=
MCF7NIXrTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTVwMUS1NVch|ryPNYfSRmg1W0GQR1XS
CAPAN-1NHewS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrmRotKSzVyPUWuNlU4ODdizszNMnrHV2FPT0WU
PSN1NG\hN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTVwMkeyN|Uh|ryPMXvTRW5ITVJ?
NCI-H292NHTrd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HBfWlEPTB;NT6zNFA1PCEQvF2=MYDTRW5ITVJ?
CPC-NM3z5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInHWWNKSzVyPUWuN|k1OTlizszNMVzTRW5ITVJ?
DoTc2-4510NEjoVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jQeWlEPTB;NT60OVM4OSEQvF2=M2nN[3NCVkeHUh?=
LB1047-RCCMmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLjRYxKSzVyPUWuOVU6OzNizszNMWPTRW5ITVJ?
MHH-ES-1NYq3WWpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDzSm1CUUN3ME21MlU6QTB5IN88US=>Mnj4V2FPT0WU
NMC-G1NWnwTIVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTVwN{CyNlch|ryPNYrX[2YzW0GQR1XS
SW1710MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jUUWlEPTB;NT63OFc2OSEQvF2=MnvoV2FPT0WU
YAPCMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\aOVJKSzVyPUWuO|YzODFizszNMonoV2FPT0WU
22RV1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGezTVZKSzVyPUWuPFAxOTlizszNNEDLWWNUSU6JRWK=
COLO-679NHP3TnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;rS|dKSzVyPUWuPFg6PDhizszNM2jTXHNCVkeHUh?=
TCCSUPMnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTVwOUOyOVkh|ryPNYruOYJjW0GQR1XS
C2BBe1NYqwbplRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHGTWM2OD13LkmzPVch|ryPNHzwNHBUSU6JRWK=
TE-15MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTZwME[2NFUh|ryPMnXlV2FPT0WU
SCLC-21HNXfaZXIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTZwMUC4OFMh|ryPMlP0V2FPT0WU
EoL-1-cellNUHrPXZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTzZnBxUUN3ME22MlE3PTZ|IN88US=>NXXtTJRjW0GQR1XS
NKM-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXrTWM2OD14LkG2O|Eh|ryPNV;5WphyW0GQR1XS
NCI-H1304NWrjbXhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjTTWM2OD14LkK3OFI5KM7:TR?=MWrTRW5ITVJ?
NB6Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\kTWM2OD14LkK5OlIzKM7:TR?=MkHVV2FPT0WU
NALM-6Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HYRWlEPTB;Nj6zN|I{KM7:TR?=MlPoV2FPT0WU
NCI-H522MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zkemlEPTB;Nj6zN|MxPiEQvF2=MV3TRW5ITVJ?
MV-4-11MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PQXmlEPTB;Nj6zO|A4QSEQvF2=M3vNXnNCVkeHUh?=
LB2241-RCCMnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEO0R5JKSzVyPU[uN|g3PjdizszNMl\EV2FPT0WU
NCI-H1417NVj5Wm9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjxXGg3UUN3ME22MlQxQDR5IN88US=>MV\TRW5ITVJ?
HT-1197M{fVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\SS5BKSzVyPU[uOVcyOjJizszNMlTRV2FPT0WU
P30-OHKNYX2eHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTZwNkK3O{DPxE1?M{TiTXNCVkeHUh?=
ALL-POMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTZwN{G5NVYh|ryPMn7zV2FPT0WU
OVCAR-4NXvKS2NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITCU2pKSzVyPU[uO|U1ODVizszNNXu5b4lLW0GQR1XS
HCC2157M1nvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTZwN{e0O|Uh|ryPNGH4XXFUSU6JRWK=
NCI-H838NWPV[YJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTMTZdwUUN3ME22Mlk3PDlizszNNXTONWJ5W0GQR1XS
NCI-H1299MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvVTWM2OD14Lkm3NFkh|ryPMoTkV2FPT0WU
SW954MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUOxN29EUUN3ME23MlIxODZ6IN88US=>NHO0VnRUSU6JRWK=
NCI-H441M3XVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rxWGlEPTB;Nz6zOFA3PSEQvF2=MWLTRW5ITVJ?
SK-MEL-2NYDlNpl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXGzTZhmUUN3ME23MlQ5Ozd|IN88US=>MmPzV2FPT0WU
KARPAS-45MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;ifWlEPTB;Nz62OVkzQSEQvF2=NV[yZWI5W0GQR1XS
CAL-54NW\vcFJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF:yS|RKSzVyPUeuPFI6PzdizszNMXzTRW5ITVJ?
KYSE-180NWnUVYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnZOFk{UUN3ME23Mlg5QTRzIN88US=>MoDBV2FPT0WU
NCI-H187Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXpWZBKSzVyPUeuPVU6PDdizszNNHvWWFdUSU6JRWK=
RT-112M2fBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XzcmlEPTB;OD6wPVY4PyEQvF2=M3:xVnNCVkeHUh?=
NCI-H1437NFfI[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXiyVZdHUUN3ME24MlA6Pzl3IN88US=>NXnY[2NzW0GQR1XS
SNU-449Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfoUGhKSzVyPUiuNlgzPzJizszNMV;TRW5ITVJ?
HCC1187M{fTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rmRmlEPTB;OD6yPVM6OSEQvF2=NHXVOVlUSU6JRWK=
NCI-H2030NHe1fWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjGWpR{UUN3ME24MlM4PzF2IN88US=>MWTTRW5ITVJ?
HuO-3N1NXrMZZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnP0TWM2OD16LkO3PFQ1KM7:TR?=NVfWeFd7W0GQR1XS
COLO-792M2rMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLpTWM2OD16LkSxOVI4KM7:TR?=NELZTJBUSU6JRWK=
MIA-PaCa-2M1[4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRThwOEW1NFgh|ryPMX\TRW5ITVJ?
SK-N-FIMnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTlwMESyOUDPxE1?MYXTRW5ITVJ?
MMAC-SFM4rBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3uUHI4UUN3ME25MlA6PzVzIN88US=>Mn7EV2FPT0WU
NCI-H28MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3v1[GlEPTB;OT6xNFQ3QSEQvF2=NETBU3NUSU6JRWK=
ETK-1MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrxbohKSzVyPUmuNlk6PzRizszNMlHCV2FPT0WU
NCI-H1993MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTlwNESyOlEh|ryPNVzVS|FwW0GQR1XS
no-11NUjH[ng{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmG0TWM2OD17LkS3NVIh|ryPMmWyV2FPT0WU
ChaGo-K-1NVTHPWV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG[5[FRKSzVyPUmuOVE2QDNizszNNV3lXplqW0GQR1XS
NCCITM{[xS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTlwNUOxOlkh|ryPNXzBW4F5W0GQR1XS
SASM2HtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXIeWxkUUN3ME2xNE4zPDhizszNNIjmSllUSU6JRWK=
A673NHr4XoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTFyLkO3NFQh|ryPNVvqN3RVW0GQR1XS
NCI-H1522NVm5bnhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzzPJdDUUN3ME2xNE4{PzB5IN88US=>MkTNV2FPT0WU
NCI-H810M{T6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfidHBKSzVyPUGwMlM6ODdizszNM335VnNCVkeHUh?=
IST-MES1NV3ZSVRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7neJFUUUN3ME2xNE41PTZ2IN88US=>MVLTRW5ITVJ?
GR-STNYjEV3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrQTWM2OD1zMD61NFI1KM7:TR?=NGLOcnhUSU6JRWK=
SUP-T1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTFyLkezNVch|ryPM4T2eHNCVkeHUh?=
NB5MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTFyLkmwNlIh|ryPMYfTRW5ITVJ?
MZ1-PCNX7i[Y9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHL6XFFKSzVyPUGwMlk2PzFizszNM3q1b3NCVkeHUh?=
SK-CO-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzvXoVKSzVyPUGwMlk6OzFizszNM1fHZnNCVkeHUh?=
Capan-2MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrvTWM2OD1zMT6zNVk5KM7:TR?=NVTsOpdoW0GQR1XS
697NIj2WlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXS[XVKSzVyPUGxMlY4PTdizszNNYjuTYZRW0GQR1XS
REHMkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4mwSmlEPTB;MUGuO|Q2OSEQvF2=MV3TRW5ITVJ?
GI-1M3K5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTFzLki2NVUh|ryPMXnTRW5ITVJ?
BB65-RCCMmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XsT2lEPTB;MUKuNFkyPiEQvF2=NFHtelBUSU6JRWK=
NCI-H1651NW\jbWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHe2OVdKSzVyPUGyMlI1PzhizszNNUfuXmU{W0GQR1XS
NCI-H1618MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETyZ3pKSzVyPUGyMlM6PzZizszNM1zMO3NCVkeHUh?=
NCI-H2081M4\vO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLHUGlKSzVyPUGyMlYyPDFizszNNFiyO2ZUSU6JRWK=
GCIYNF6xbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLkTWM2OD1zMj63NlE{KM7:TR?=NWXscIxxW0GQR1XS
NYNVvpdZdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvYTWM2OD1zMz6wOlQ{KM7:TR?=NFmyW|ZUSU6JRWK=
PANC-03-27MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfzTWM2OD1zMz6wPFA4KM7:TR?=MXnTRW5ITVJ?
BHYNYfvT4UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTF|LkKxNlEh|ryPM2HHfXNCVkeHUh?=
SK-OV-3MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTF|LkO3OlMh|ryPM{SwNXNCVkeHUh?=
5637NE\M[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDtfVVKSzVyPUGzMlc4PTlizszNMmfKV2FPT0WU
LC-1FMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoD3TWM2OD1zND6wN|U3KM7:TR?=NX\sbFFlW0GQR1XS
SNB75M4Trc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV71PGNPUUN3ME2xOE4xOzh|IN88US=>M1jQd3NCVkeHUh?=
CHP-212MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHFTWM2OD1zND6wOFY1KM7:TR?=MXLTRW5ITVJ?
HT-1376MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHjTWM2OD1zND6xNVI3KM7:TR?=MWPTRW5ITVJ?
MONO-MAC-6MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4ThUWlEPTB;MUSuNVUxOiEQvF2=NF7FZ4pUSU6JRWK=
CA46M2rD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTSN3JKSzVyPUG0MlE5OjdizszNNUXqeHFDW0GQR1XS
SCC-15MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDTNWRKSzVyPUG0MlU2QDNizszNMWPTRW5ITVJ?
ATN-1NYjoXZBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVK0XHQ6UUN3ME2xOE43PjJ5IN88US=>MXrTRW5ITVJ?
NCI-H2405MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DkOGlEPTB;MUSuPFE2PyEQvF2=NGG4UJNUSU6JRWK=
NCI-H716M2fPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTF2Lki0PVMh|ryPM1zrNHNCVkeHUh?=
SW620NV[3U4dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEj3bWpKSzVyPUG0MlkxOTRizszNNFThTZJUSU6JRWK=
NCI-H226MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjX[4NvUUN3ME2xOE46ODh3IN88US=>MlzDV2FPT0WU
SW962MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmf0TWM2OD1zND65OFMzKM7:TR?=NEjzSFlUSU6JRWK=
KYSE-150M4HMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXZSpNVUUN3ME2xOE46PTVizszNMV\TRW5ITVJ?
OCUB-MNWfROZAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTF2Lkm4PFMh|ryPMo\xV2FPT0WU
ES7NYD6SZg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTF3LkC5PFQh|ryPNYnmWpVOW0GQR1XS
SW1463NXrOOmx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTF3LkSyNlMh|ryPM4\pZ3NCVkeHUh?=
CAKI-1MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTF3LkWzOFYh|ryPMnnYV2FPT0WU
MKN28NVLESG9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fLVGlEPTB;MUWuOVQ4QSEQvF2=NXG1RZNxW0GQR1XS
SW13NI\DUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTF3Lk[xPEDPxE1?NYjZeWZZW0GQR1XS
A3-KAWMnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\RSYZKSzVyPUG1Mlk3QTdizszNMX;TRW5ITVJ?
LU-65M2PSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnq[2xKSzVyPUG1Mlk4PjhizszNMkPWV2FPT0WU
Calu-1M2nw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTF4LkCzOlgh|ryPMWPTRW5ITVJ?
ST486NHi2XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXu1RpZVUUN3ME2xOk4xPDNzIN88US=>MUfTRW5ITVJ?
BB30-HNCMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTF4LkGyOFYh|ryPNETGWVhUSU6JRWK=
EGI-1NGPve2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIq0clhKSzVyPUG2MlQ1PiEQvF2=MWjTRW5ITVJ?
SH-4MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTF4LkS3N|Eh|ryPMknxV2FPT0WU
MN-60MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rnXWlEPTB;MUeuNlI6PyEQvF2=NVrxb2pVW0GQR1XS
MPP-89M2PrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIi0PJVKSzVyPUG3MlI1PTlizszNNXPqRpJXW0GQR1XS
A2780NX3JdZhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHK0fmxKSzVyPUG3MlQyOzlizszNM3HkcHNCVkeHUh?=
DaoyNEPHdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTuTWM2OD1zNz60Olk2KM7:TR?=NILjcnRUSU6JRWK=
NCI-H2126MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTF5LkS3O|Eh|ryPNFrtbJhUSU6JRWK=
NCI-H1563MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTF5LkS5NVch|ryPNF\DVHZUSU6JRWK=
8-MG-BANF\GSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrrTWM2OD1zNz62OlQ5KM7:TR?=M2HD[HNCVkeHUh?=
786-0MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorJTWM2OD1zNz64N|U{KM7:TR?=NV72bWttW0GQR1XS
AM-38NITjcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTF5LkmzNFYh|ryPNWizW415W0GQR1XS
COLO-824M3fmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGSxTGRKSzVyPUG4MlQ1OzZizszNNXPtbmcxW0GQR1XS
SK-MEL-30M4LaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUf1T25VUUN3ME2xPE42ODh{IN88US=>MUPTRW5ITVJ?
CESSM33EOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTUVJBLUUN3ME2xPE44PjB7IN88US=>M1X4XnNCVkeHUh?=
BL-70NF\FZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTF6LkixOVYh|ryPMlW1V2FPT0WU
NCI-H2170MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\MV|FKSzVyPUG4MlkyPzlizszNNFjje|BUSU6JRWK=
HT-3MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjCeWI4UUN3ME2xPE46QDNizszNMkXzV2FPT0WU
BOKUNWSyWoNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTF7LkCzPFEh|ryPNU\ZcWZVW0GQR1XS
HPAF-IIMkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYS3UYZoUUN3ME2xPU4{ODF3IN88US=>M3;j[nNCVkeHUh?=
KGNM136Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIf0fXRKSzVyPUG5MlQ4PjVizszNNX;WOXdFW0GQR1XS
MC-CARNVn0cYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX6xTnFUUUN3ME2xPU43OzF|IN88US=>Ml\ZV2FPT0WU
BHT-101NVryVXRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDTTWM2OD1zOT63O|ch|ryPM1nv[nNCVkeHUh?=
SW1783MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTF7Lke4NFYh|ryPNIL5XXZUSU6JRWK=
KP-N-YNMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XDO2lEPTB;MkCuNFI3OiEQvF2=NYSycG9kW0GQR1XS
LU-165M{\CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTJyLkW1O|Eh|ryPMonnV2FPT0WU
GOTOMnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrJTWM2OD1{MD62OFUyKM7:TR?=Mlm3V2FPT0WU
EFM-19NWrPc491T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXBZ5M{UUN3ME2yNU4xPzF4IN88US=>NWHodIp5W0GQR1XS
CTV-1Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLvTWM2OD1{MT6xNFU1KM7:TR?=MoGyV2FPT0WU
HELMnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrze2NZUUN3ME2yNU41OjF4IN88US=>MkG5V2FPT0WU
SNU-C2BNHuyepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2S2WmlEPTB;MkGuOFI3KM7:TR?=Mli1V2FPT0WU
ECC4MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUX6enZMUUN3ME2yNU44ODdizszNNXXuUIhrW0GQR1XS
NEC8NH7ke3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGT4U4lKSzVyPUKxMlg{PjhizszNNUDhXpZRW0GQR1XS
KMOE-2NHf3bo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3e0UGlEPTB;MkGuPFkzOSEQvF2=NYrjNmZOW0GQR1XS
NCI-H524Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzXOmNWUUN3ME2yNk4xQDB6IN88US=>M4WxbnNCVkeHUh?=
WSU-NHLNWTiUHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HGZWlEPTB;MkKuNVU4PyEQvF2=NFu0T|RUSU6JRWK=
SF126NGnEV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTxWWtKSzVyPUKyMlI1PjlizszNMYXTRW5ITVJ?
HOP-92MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXETWM2OD1{Mj6zNVY4KM7:TR?=M{DOPXNCVkeHUh?=
CTB-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTJ{LkS2O|ch|ryPNIT2UnlUSU6JRWK=
KYSE-270MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTJ{LkmzOVch|ryPMkj4V2FPT0WU
SK-MEL-24NEjaRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLvTWM2OD1{Mz6xPFch|ryPNXzxNlhbW0GQR1XS
Calu-3M3nod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTJ|LkKxNlgh|ryPMYLTRW5ITVJ?
GAMGMk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\FVJNKSzVyPUKzMlI{PjdizszNMYjTRW5ITVJ?
SW1573NVnqVmw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWT6NZFDUUN3ME2yN{44PDF3IN88US=>M3\k[nNCVkeHUh?=
MHH-NB-11NYPU[VVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDYTWM2OD1{ND6wNVk1KM7:TR?=NFnuXm1USU6JRWK=
TK10NH\4T2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfYVGVKSzVyPUK0MlUxOTNizszNMoDEV2FPT0WU
LB373-MEL-DMkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTJ2Lk[wOlQh|ryPMXXTRW5ITVJ?
KALS-1NUnoU4NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPrcIVKSzVyPUK0Mlc{OjdizszNMUjTRW5ITVJ?
HUTU-80NHf3WVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTJ3LkiwN|Ih|ryPNY\ibYxjW0GQR1XS
HuP-T3NX;zPXpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWmxN2d3UUN3ME2yOk4yPjd2IN88US=>MV7TRW5ITVJ?
OE19MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorFTWM2OD1{Nj6yNVU{KM7:TR?=M1mxS3NCVkeHUh?=
J82NXHtVZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPmW3BVUUN3ME2yOk4zPDdzIN88US=>MlzhV2FPT0WU
DU-4475NILaT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFG2Z2JKSzVyPUK2MlM5OTlizszNMl3PV2FPT0WU
DMS-53M4ewbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PNWmlEPTB;Mk[uOVE{QCEQvF2=M2nxXXNCVkeHUh?=
COLO-741M3rNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml23TWM2OD1{Nj64N|Q1KM7:TR?=M2HJd3NCVkeHUh?=
SW48M3G3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHGXWNKSzVyPUK2Mlg5OiEQvF2=Mo\ZV2FPT0WU
IGR-1NHXl[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\3VGlEPTB;Mk[uPVM{PCEQvF2=NHHudI5USU6JRWK=
639-VMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTJ5LkCyOFUh|ryPNHXRXYJUSU6JRWK=
LK-2NFqwcGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTJ5LkSxOFEh|ryPM37MNHNCVkeHUh?=
NCI-H2347NHTFNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTJ5Lkm2PVkh|ryPNWXPOnFPW0GQR1XS
NCI-H2228MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\3TWM2OD1{OD6wPVA2KM7:TR?=M3;CO3NCVkeHUh?=
LS-123NWnZclFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrQUmM1UUN3ME2yPE4yOjZ{IN88US=>MUnTRW5ITVJ?
U031MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\LZWlEPTB;MkiuNlUzKM7:TR?=MVHTRW5ITVJ?
NCI-H1792MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fk[mlEPTB;MkiuOFczOSEQvF2=M2CwXXNCVkeHUh?=
NCI-H2087NHLQZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvaS4tKSzVyPUK4Mlc2PTJizszNMYTTRW5ITVJ?
NCI-H2342NXPYeXc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTITWZKSzVyPUK5MlUzODhizszNMXHTRW5ITVJ?
SW626MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;1TWM2OD1{OT63OVYh|ryPMnP4V2FPT0WU
LB2518-MELM2XNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3jTWM2OD1{OT64NVUh|ryPNIjMW4tUSU6JRWK=
RXF393MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTWTWM2OD1|MD6wPVUzKM7:TR?=M2fPfHNCVkeHUh?=
LC4-1MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLR[Ho2UUN3ME2zNE4{ODl{IN88US=>MlvLV2FPT0WU
NCI-H1694MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTNyLk[2NlQh|ryPM1fFZnNCVkeHUh?=
K5MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTNyLkm3NFIh|ryPMVXTRW5ITVJ?
HDLM-2NYH5dnczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTNyLkm3NlUh|ryPM3HlcHNCVkeHUh?=
BCPAPNXXWbVR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofOTWM2OD1|MT64N|c6KM7:TR?=MmXuV2FPT0WU
BC-3MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjmTWM2OD1|Mj6xOFA{KM7:TR?=MWHTRW5ITVJ?
LB996-RCCMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTHTWM2OD1|Mj6yN|U5KM7:TR?=MWLTRW5ITVJ?
NCI-H2009MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HUeWlEPTB;M{KuOFk5OSEQvF2=NHLaSZFUSU6JRWK=
HTC-C3MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkD4TWM2OD1|Mz63OVE6KM7:TR?=M4\1NnNCVkeHUh?=
LAMA-84M3rxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTN2LkS0NFch|ryPMnXTV2FPT0WU
CCRF-CEMM33kR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTqTWM2OD1|ND61O|E2KM7:TR?=NFLYVXZUSU6JRWK=
AN3-CAM1HERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXqyZpZRUUN3ME2zOU4xPTZ6IN88US=>MYfTRW5ITVJ?
NCI-H1734MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fZOmlEPTB;M{WuNlU3OSEQvF2=NUK2NlZSW0GQR1XS
Ca-SkiNIL6W3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\6OmVKSzVyPUO1MlQyODFizszNMXzTRW5ITVJ?
U-266NXnocZNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTN3Lk[xNVQh|ryPMV7TRW5ITVJ?
SBC-5M2HJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTN3Lke3PFEh|ryPMV;TRW5ITVJ?
GT3TKBM2T2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFi0XpBKSzVyPUO3MlEyPSEQvF2=NYXPXmlWW0GQR1XS
MDA-MB-175-VIIMmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLK[JNKSzVyPUO3MlIzPDhizszNNEfmeGxUSU6JRWK=
PFSK-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTN5LkK0N|Uh|ryPMUXTRW5ITVJ?
IMR-5M1rJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTN5LkK0PFch|ryPMWjTRW5ITVJ?
DaudiNFPNWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDETWM2OD1|Nz6zOVk4KM7:TR?=MnH2V2FPT0WU
A498MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmCyTWM2OD1|Nz63NlE5KM7:TR?=MU\TRW5ITVJ?
SCC-4Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTN5Lke4OFMh|ryPMUXTRW5ITVJ?
COLO-680NM{GyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\kbXNKSzVyPUO4MlI5QDVizszNNWiwOJdXW0GQR1XS
SK-MES-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLaVWNuUUN3ME2zPE4{OjF3IN88US=>MX3TRW5ITVJ?
SRM3f0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTN6LkW0PVUh|ryPMmPBV2FPT0WU
LNCaP-Clone-FGCM3;GPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHDXodOUUN3ME2zPE42PjN5IN88US=>NFLqeXFUSU6JRWK=
SK-HEP-1MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3ywVGlEPTB;M{iuO|gzOiEQvF2=NVnFTINEW0GQR1XS
BPH-1NGe2PFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rQUGlEPTB;M{iuPFMzQSEQvF2=MWHTRW5ITVJ?
NCI-H1755MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDSTXBxUUN3ME2zPU42QDF5IN88US=>MVLTRW5ITVJ?
LXF-289NFXYWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFz2dnRKSzVyPUO5MlgxQDRizszNNV3DR4M2W0GQR1XS
SW1088NU\HcFhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXvTWM2OD12MD6yNVA4KM7:TR?=NUi0cGV[W0GQR1XS
MOLT-4NV21NZhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI[xVolKSzVyPUSwMlI6ODFizszNM1HNWHNCVkeHUh?=
AsPC-1M3nsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTRyLkS1PFMh|ryPMYnTRW5ITVJ?
HOP-62MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTRyLk[1Olgh|ryPMXnTRW5ITVJ?
A172MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4H0OmlEPTB;NECuPFUyOSEQvF2=NV:1TZVkW0GQR1XS
SN12CMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;aTWM2OD12MD65N|g2KM7:TR?=M3\N[XNCVkeHUh?=
MDA-MB-231M3vOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2riW2lEPTB;NECuPVg6QCEQvF2=NXXOXFFKW0GQR1XS
RPMI-2650M135XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXO3Z5VWUUN3ME20NU4yPTl|IN88US=>M37HSnNCVkeHUh?=
KYSE-140M2\nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHPNoFDUUN3ME20NU45OTJ|IN88US=>MX7TRW5ITVJ?
KINGS-1M2HIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLZSYRxUUN3ME20Nk41Pjl5IN88US=>M{X0T3NCVkeHUh?=
HSC-3MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LudmlEPTB;NEKuOlY3OSEQvF2=NGPCV5dUSU6JRWK=
PC-14Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2i3NmlEPTB;NEOuNVg5OiEQvF2=MUnTRW5ITVJ?
COR-L105NGTJbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYn5bpFJUUN3ME20N{43PTB{IN88US=>NXr3b5dsW0GQR1XS
BE-13MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfyN5VKSzVyPUS0MlI{PzFizszNMVzTRW5ITVJ?
NCI-H661MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTR2LkK5OVgh|ryPMknlV2FPT0WU
IST-MEL1NH\5PYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV:5[JZ4UUN3ME20OE4{PTl7IN88US=>NHSwcHNUSU6JRWK=
HCC1806MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LJd2lEPTB;NESuOVg4OyEQvF2=M3;1SXNCVkeHUh?=
COLO-800MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LLbGlEPTB;NESuPFQ2OyEQvF2=MYnTRW5ITVJ?
IST-SL2NIDzZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnDbpRKSzVyPUS1MlEzPDdizszNNVPacIw5W0GQR1XS
8305CM{TqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYK3RZBkUUN3ME20OU4{ODlizszNMmTIV2FPT0WU
UACC-62Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTR4LkK4O|Uh|ryPM2nNTnNCVkeHUh?=
COR-L23M1L4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXSTWM2OD12Nz6xPVkh|ryPNUHkWHB{W0GQR1XS
EFE-184NV\4RVFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHz6clFKSzVyPUS3MlM5QCEQvF2=M2HGeHNCVkeHUh?=
DMS-114M3n0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTR5LkSxOFkh|ryPMnnHV2FPT0WU
KYSE-520M2TNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTR6LkWzNVUh|ryPMni1V2FPT0WU
SNG-MNYTFfVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nyfWlEPTB;NEmuOFM1KM7:TR?=M{naWnNCVkeHUh?=
A2058NX;xdmNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFm0NWVKSzVyPUS5MlQ5QDVizszNM4n5ZXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

Cell Assay: [1]

Cell lines MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
Concentrations 0.02-0.8 μM
Incubation Time 3 days
Method For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

Animal Study: [1]

Animal Models IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
Formulation 25 mM tartaric acid
Dosages 25 mg / kg and 75 mg / kg
Administration Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Mulvihill MJ, et al. Future Med Chem, 2009, 1(6), 1153-1171.

[2] McKinley ET, et al. Clin Cancer Res, 2011, 17(10), 3332-3340.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02057380 Active, not recruiting Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research a  ...more University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2

view more

Chemical Information

Download OSI-906 (Linsitinib) SDF
Molecular Weight (MW) 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

Customer Product Validation (3)


Click to enlarge
Rating
Source Cancer Res 2013 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck
Method Cell proliferation and growth assays
Cell Lines PFR3 cells
Concentrations 1 μM
Incubation Time
Results The IC50 of PFR3 cells for PF299804 was more than 100 fold lower with the combination of OSI-90 than with PF00299804 alone.

Click to enlarge
Rating
Source Cancer Res 2011 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck
Method [18 F]FDG –PET/ Western blot
Cell Lines MCF-7 cells/athymic mice
Concentrations 50 mg/kg/day
Incubation Time 6 weeks
Results mice without palpable tumors were randomized to treatment with vehicle or OSI-906. Six of 20 control mice (30%) developed tumors, whereas none of the 20 OSI-906–treated mice did (Fig. A). OSI-906 inhibited tumor growth compared with vehicle (Fig. B; P < 0.05). OSI-906–treated tumors exhibited markedly lower levels of phosphorylated IGF-IR, InsR, IRS-1, AKT, and S6 compared with vehicle controls (Fig. C). FDG uptake was significantly decreased 4 hours after a single dose of OSI-906 com-pared with baseline (Fig. D)

Click to enlarge
Rating
Source OSI-906 (Linsitinib) purchased from Selleck
Method Flow cytometry/ Western Blotting
Cell Lines CLL B cells
Concentrations 1 µM
Incubation Time 24 h
Results three structurally unrelated IGF1R inhibi tors AG1024, Picropodophyllin (PPP) and linsitinib significantly reduced the cellular viability of primary CLL cells ( Figure A) and reduced levels of phosphorylated IGF1R and IRS-1 (Figure B,C). AG1024, which showed the strongest effect on viability, caused a dose-dependent decrease in the levels of phosphorylated Src, PI3K, Akt, MEK and ERK (Figure D).

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related IGF-1R Products

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • BMS-536924

    BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

  • NVP-AEW541

    NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.

  • NVP-ADW742

    NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

  • GSK1904529A

    GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.

  • BMS-754807

    BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

    Features:Muti-inhibitor of the IGR-1R/IR family.

  • AG-1024

    AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).

  • PQ 401

    PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Recently Viewed Items

Tags: buy OSI-906 (Linsitinib) | OSI-906 (Linsitinib) supplier | purchase OSI-906 (Linsitinib) | OSI-906 (Linsitinib) cost | OSI-906 (Linsitinib) manufacturer | order OSI-906 (Linsitinib) | OSI-906 (Linsitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us